Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers

•CDP-choline affects human brain oscillations.•Oscillatory changes mimic nicotinic stimulation.•These observations allow extensions to clinical populations. CDP-choline (cytidine-5′-diphosphocholine) is a phospholipid used to treat cognitive disorders, presumably repairing and maintaining brain cell...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience letters 2015-03, Vol.591, p.121-125
Main Authors: Knott, Verner, Salle, Sara de la, Smith, Dylan, Choueiry, Joelle, Impey, Danielle, Smith, Meaghan, Beaudry, Elise, Saghir, Salman, Ilivitsky, Vadim, Labelle, Alain
Format: Article
Language:English
Subjects:
Brain - drug effects
Brain - physiology
Brain Mapping
Choline
Cognition
Cross-Over Studies
Cytidine Diphosphate Choline - pharmacology
Cytidine-5′-diphosphocholine
Double-Blind Method
Electroencephalography
Humans
Male
Nicotinic Agonists - pharmacology
Nicotinic receptors
Oscillations
Reference Values
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•CDP-choline affects human brain oscillations.•Oscillatory changes mimic nicotinic stimulation.•These observations allow extensions to clinical populations. CDP-choline (cytidine-5′-diphosphocholine) is a phospholipid used to treat cognitive disorders, presumably repairing and maintaining brain cell membranes. Additional mechanisms may include enhanced cholinergic neurotransmission as the α7 nicotinic receptor actions of choline and increased acetylcholine synthesis accompanying CDP-choline administration may modulate brain oscillations underlying cognitive processes. This study utilizes electroencephalographic (EEG) recordings in healthy volunteers to evaluate CDP-choline induction of an oscillatory response profile associated with nicotinic stimulation. Resting state EEG was acquired in 24 male volunteers administered low (500mg) and moderate (1000mg) doses of CDP-choline in a randomized placebo-controlled, crossover trial. Consistent with nicotinic agonist treatment, spectral analysis showed dose-dependent reductions in delta and increases in alpha oscillations, which were also accompanied by decreases in beta and gamma oscillatory activity. These findings support the posit that CDP-choline cognitive enhancement involves multiple mechanisms including facilitated nicotinic cholinergic action.
ISSN:0304-3940
1872-7972
DOI:10.1016/j.neulet.2015.02.032